Aaron Kantoff


Aaron Kantoff is currently a board member of RayzeBio and Ceptur Therapeutics, two private biotech companies for which he was a founding board member. Aaron is a former Venture Partner on the Medicxi investment team. Prior to joining Medicxi, Aaron was a partner with Apple Tree Partners (ATP), where he was a key member of the life science investment team since 2011. While at ATP, he played a leading role in assembling several ATP portfolio companies, previously serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk), Elstar Therapeutics, Limelight Bio, and Syntimmune (acquired by Alexion). During his time at ATP, Aaron was also a Board Observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments.

Prior to joining ATP, Aaron held roles in private equity and investment banking.

Aaron received a BS in Finance and International Business from NYU Stern School of Business.

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser